Alzheimer’s Disease Market

Market Overview:

The 7 major Alzheimer’s Disease markets are expected to exhibit a CAGR of 7.36% during 2023-2033.

Alzheimer’s Disease Market is primarily driven by a rising geriatric population, who are more prone to neurodegenerative disorders. In over 90% of patients with Alzheimer’s, symptoms do not appear till the age 60. Furthermore, incidence of the disease rises with age and doubles every 5 years after age 65. In addition to the rising ageing population, Alzheimer’s disease market is also driven by improving diagnosis and drug treatment rates which includes a rising adoption of newer diagnostic techniques for early diagnosis. Furthermore, the ongoing development of several novel therapeutics that have a strong safety and efficacy profile is also expected to catalyse the growth of the market in the coming years.

Alzheimer's Disease (AD) refers to a neurodegenerative disorder characterized by the degeneration of nerve cells in several areas of the brain that control thought, memory, and language. The most common symptoms include memory impairment, depression, loss of inhibitions, etc. As the disease progresses, symptoms may include issues with language, disorientation, mood swings, loss of motivation, self-neglect, and behavioral problems. Alzheimer’s disease currently represents the seventh leading cause of death among all diseases and one of the biggest causes of disability and dependency among the geriatric population. Alzheimer’s disease has physical, psychological, social, and economic impacts, not only for individuals living with the disease, but also for their carers, families, and society at large.

IMARC Group’s new report "Alzheimer’s Disease Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity and Forecast" provides an exhaustive analysis of the Alzheimer’s Disease market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. The report provides an in-depth understanding of current and future landscape of the Alzheimer’s Disease market. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool for Alzheimer’s Disease across the seven major markets. According to the report, among the seven major markets, the United States has the largest patient pool for Alzheimer’s Disease and also represents the largest market for Alzheimer’s Disease treatment. Furthermore, the current Alzheimer’s Disease treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the Alzheimer’s Disease market in any manner.

Time Period of the Study

• Base Year: 2022
• Historical Period: 2017-2022
• Market Forecast: 2023-2033

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, Current and Future Epidemiology Scenario
• Historical, Current and Future Performance of the Alzheimer’s Disease Market
• Historical, Current and Future Performance of Various Therapeutic Categories in the Alzheimer’s Disease Market
• Sales of Various Drugs Across the Alzheimer’s Disease Market
• Reimbursement Scenario in the Alzheimer’s Disease Market

Competitive Landscape:

This report also provides a detailed analysis of the current Alzheimer’s Disease marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

Key Questions Answered in this Report:

Market Insights

• How has the Alzheimer’s Disease market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2022 and how is it expected to be in 2033?
• What was the country-wise size of the Alzheimer’s Disease market across the seven major markets in 2022 and how will it look like in 2033?
• What is the growth rate of the Alzheimer’s Disease market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the Alzheimer’s Disease market?

Epidemiology Insights

• What is the size of the Alzheimer’s Disease patient pool (2017-2022) across the seven major markets?
• What would be the forecasted patient pool (2023-2033) of Alzheimer’s Disease across the seven major markets?
• What are the key factors driving the epidemiological trend of Alzheimer’s Disease?
• What will be the growth rate of Alzheimer’s Disease patients across the seven major markets?

Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed Alzheimer’s Disease drugs and what are their market performance?
• What are the key pipeline Alzheimer’s Disease drugs and how are they expected to perform in the coming years?
• How safe are the current marketed Alzheimer’s Disease drugs and what are their efficacies?
• How safe are the late-stage pipeline Alzheimer’s Disease drugs and what are their efficacies?
• What are the current treatment guidelines for Alzheimer’s Disease drugs across the seven major markets?
• Who are the key companies in the Alzheimer’s Disease market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the Alzheimer’s Disease market?